演讲专家
部分演讲专家(已确认)

Elizabeth DeLong, Ph.D.
Duke University Medical Center.

Dr. DeLong is Professor and Chair, Department of Biostatistics and Bioinformatics, Duke University Medical Center.  With more than 20 years of biostatistics, clinical research, and bioinformatics experience, her responsibilities have included administrative and data analytic functions, as well as statistical methods development.  She was recently the Principal Investigator for the analysis center of ASCERT, a unique collaboration between two professional societies to study comparative effectiveness of coronary artery bypass surgery relative to percutaneous coronary intervention for stable coronary artery disease. . Currently she holds the Duke sub-contract for a PCORI methods grant exploring differences in causal inference approaches to the analysis of observational data, with application to survival for ischemic heart disease.  She also leads the Biostatistics and Study Design Working Group for the Coordinating Center of the PCORI-funded NIH Health Care Systems Research Collaboratory, which shares common practices across several large pragmatic clinical trials.  Members of the Core review the study designs, sample size considerations, and analysis plans for proposed trials and work with the statistical personnel on these projects to ensure appropriate statistical input.  Her experience in coordinating and implementing statistical practices across a diverse spectrum of activities will be an asset for this NSF NRT award.

DeLong博士是杜克大学医学院生物统计学和生物信息学系教授。拥有20多年的生物统计、临床研究和生物信息学的经验,DeLong博士主要负责数据分析以及统计方法开发的工作。DeLong博士是ASCERT分析中心的首席研究员,旨在研究对于稳定冠状动脉疾病的冠状动脉搭桥手术相对于经皮冠状动脉介入治疗的效果比较。 DeLong博士目前还主持PCORI资助杜克大学的子合同,应用于缺血性心脏病生存的因果推理方法与所观察数据分析差异的探索。DeLong博士还领导了PCORI出资的NIH医疗保健系统研究合作协调中心的生物统计学和研究设计工作组,该研究机构分享了多项大型临床试验中的实践经验。 核心成员审查研究设计,样本量考虑因素和拟议试验分析计划,并与这些项目的统计人员合作,以确保适当的统计投入。DeLong博士在不同的项目协调和实施统计实践方面的经验将成为NSF NRT奖的一项资产。

Harry Yang, Ph.D.
Senior Director and Head of Statistical Sciences at MedImmune
Vice Chair of USP Statistics Expert Committee

Harry Yang is Senior Director and Head of Statistical Sciences at MedImmune. He is also the Vice Chair of USP Statistics Expert Committee and has participated in industry initiatives related to Quality by Design, analytical method development and validation, and sterile drug product bioburden testing. He is a frequent invited speaker at national and international conferences and workshops. He was also invited to develop statistical courses and conduct the training at the Food and Drug Administration, United States, United Pharmacopeia, and Peking University. Harry has published three statistical books and over 90 papers and book chapters. He received his BS and MS degrees in Applied Mathematics from Peking University, and Ph.D. in Statistics from the University of Pittsburgh.

 

杨鹤飞博士毕业于北京大学应用数学专业,博士毕业于Pittsburgh大学的统计学专业;是MedImmune公司的高级经理和统计部门负责人,他也是USP统计专家委员会的副主任委员;他将统计知识运用于医药行业生产项目的质量设计、分析方法的开发和验证、以及无菌产品微生物污染水平测试等具体工作中,取得很多成功的经验。是美国国内和国际会议的高频次演讲者;并曾被邀请来为FDA、USP、和北京大学设计统计课程并进行培训。杨博士已出版三本统计学专著,发表论文90余篇。


Xiaofei Wang, Ph.D.
Duke University Medical Center.

Xiaofei Wang obtained his Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill. He is currently an Associate Professor of Biostatistics and Bioinformatics at Duke University School of Medicine, a full member of Duke Cancer Institute (DCI), and the Director of Statistics of the Alliance Statistics and Data Center. The Alliance for Clinical Trials in Oncology (Alliance) is part of the National Cancer Institute’s Clinical Trials Network (NCTN). He has been closely involved in design and analysis of national cancer clinical trials and translational studies in the past fourteen years at Alliance, CALGB and DCI. He is an associate editor for Statistics in Biopharmaceutical Research and the co-guest editor of the special issue on Precision Medicine in Cancer Clinical Research for Journal of Biopharmaceutical Statistics. He has served on several review panels for NIH and FDA grants. His methodology research is focused on the development of novel designs and methods for biomarker-integrated clinical studies and the method for analyze patient data assembled from multiple sources.

 

王晓飞,北卡罗来纳大学教堂山分校生物统计学系获得博士学位,目前就职于杜克大学医学院生物统计学和生物信息学系,担任副教授一职,同时也是杜克癌症研究所(DCI)的正式成员和联盟统计数据中心的统计总监。肿瘤学临床试验学会是国家癌症研究所临床试验联盟的一部分。过去十四年来他一直都密切参与国家癌症临床试验设计和分析工作。王晓飞教授是“生物制药研究统计”的副主编,“生物药物统计学杂志”癌症临床研究精神医学专刊的共同客座编辑。他也曾为NIH和FDA的审查小组工作。王晓飞教授主要是通过利用生物标志物同临床患者数据进行整合来进行研究分析。

 

 

William. Ed Hammond, Ph.D.
Duke Center for Health Informatics, Duke Clinical & Translational Science Institute

William. Ed Hammond, PhD has extensive experience in the design and implementation of electronic health records, starting in 1970. He has been active in the development and use of standards, internationally, since the early 1980s. His interests in informatics range from genomics, research, coordination of care, public health and population health. Dr. Hammond’s academic and industry leadership include, past president of the American Medical Informatics Association (AMIA) and AMIA Board member, President and Fellow of the American College of Medical Informatics, three terms as Chair of Health Level Seven International and several HL7 Work Group committees, two terms as the Convenor of ISO Technical Committee 215, Working Group 2 and the current Ambassador to Developing Countries and was the inaugural chair of the Joint Initiative Council of ISO/CEN/HL7. He was Chair of the Data Standards Working Group of the Connecting for Health Public-Private Consortium and served on the Board of the eHealth Initiative. He also served as Chair of the Computer-based Patient Record Institute and on the CPRI Board. He was a Chair of ACM SIGBIO, an advisor to the American Hospital Association on health data standards and related matters, and chair of the Steering Committee for the Rockefeller-sponsored Open Enterprise eHealth Architecture Framework Project. He just finished a term as a member of the Lister Hill National Center Board of Scientific Advisors. He is currently Secretary of HL7, Chair of the HL7 U.S. Realm Technical Steering Committee, and a member of the Executive Board of SafeBioPharma. He is a member of the NCHICA Board of Directors. He is involved in PCORI, Health Collaboratory, Data Visualization, and Early Check research initiatives. He is the FHIR ® Initiator for ONC Structured Data Capture Initiative. Dr. Hammond served as a member of the Institute of Medicine Committee on Patient Safety Data Standards. He was a member of the National Library of Medicine Long Range Planning Committee and a member of the Healthcare Information Technology Advisory Panel of the Joint Commission on Accreditation of Healthcare Organizations. He has served on a number of NIH review committees, testified on a number of occasions for NCVHS and has presented to several IOM committees. Dr. Hammond has served and is serving on a number of editorial boards and has published over 350 technical articles.

 

William. Ed Hammond博士是杜克临床和转化科学研究所卫生信息中心主任,杜克大学卫生技术对策部门应用信息研究主任,临床信息学管理专家学术事务部门主任, 药学院社区和家庭医学教授,护理学院兼职教授,福库商学院教授,杜克大学生物医药工程系名誉教授,William. Ed Hammond博士从1970开始就从事电子健康记录的设计和实施,具有丰富的经验。自20世纪80年代初以来,他一直致力于国际标准的制定和使用,他在信息学领域的兴趣包括基因组学、研究、协调护理、公共卫生和人口健康。

Shein-Chung Chow, Ph.D.
Duke University Medical Center.

Shein-Chung Chow, Ph.D. is currently a Professor at the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC. Prior to joining Duke, Dr. Chow also held various positions in the pharmaceutical industry. Dr. Chow is the Editor-in-Chief of the Journal of Biopharmaceutical Statistics and the Biostatistics Book Series at Chapman and Hall/CRC Press of Taylor & Francis Group. He is an ASA Fellow (1995). He was recently appointed as Special Government Employee (SGE) by the FDA. In that capacity, Dr. Chow will serve as an Advisory Committee member and consultant to the FDA. Dr. Chow is the author or co-author of over 280 methodology papers and 28 books.

 

周贤忠博士现为杜克大学医学院生物统计和生物信息学系教授;此前从在制药企业工作多年,并担任过各种不同位置,在制药行业积累了丰富的经验。周教授也是《Journal of Biopharmaceutical Statistics》和《Biostatistics Book Series》的主编;也是ASA的委员。最近,也被FDA聘为“特别政府雇员(SGE)”,主要作为FDA顾问委员会委员,并提供咨询。作为作者和合作作者发表了280篇以上的论文和28本专著。

 


冯国双,副研究员
北京儿童医院

冯国双,资深统计分析师,目前为北京儿童医院临床流行病与循证医学中心副研究员,具有十多年的SAS统计分析经验。主编《医学案例统计分析与SAS应用》(第一版、第二版)、《医学研究中的logistic回归分析及SAS实现》(第一版、第二版)、《医学实验设计分析与SAS实现》、《小白学SAS》等4部统计应用专著,在国际国内杂志共发表专业文章60余篇。
目前任“现场统计研究会空间统计分会”理事、“中华预防医学会中国生物统计学会”青年委员、“中华医学会临床流行病与循证医学分会”青年委员、“北京医学会临床流行病与循证医学分会”青年委员、“北京市免疫规划和疫苗评价专家委员会”专家委员,担任《中华预防医学杂志》、《中华全科医师杂志》、《慢性病学杂志》等杂志的编委,《中华医学杂志》、《中华精神科杂志》、《中华眼科杂志》、《中华护理杂志》等杂志审稿专家。在多家科研机构、学校院所等进行SAS或统计相关的培训和讲座,具有丰富的统计培训经验。

 

Dr. Feng Guoshuang, who worked in Beijing Children’s hospital, is a senior statistician with more than ten-year data analysis experiences. He had more than sixty papers and four books published. He is the member of Beijing Immunization programme and vaccine evaluation expert committee, member of Chinese Association for Applied Statistics, Chinese biostatistics society, Chinese society of Clinical Epidemiology and evidence-based medicine, Beijing society of Clinical Epidemiology and evidence-based medicine, et al. He is editorial board member of Chinese Journal of Preventive Medicine, Chinese Journal of General Practitioners and Chronic Pathematology Journal. He is also the peer reviewer of National Medical Journal of China, Chinese Journal of Neurology, Chinese Journal of Ophthalmology, et al.

向荣武,副教授
沈阳药科大学

向荣武,副教授,硕士生导师,沈阳药科大学医学设备研究所副院长。向教授曾获得辽宁省当代本科数学建模数学竞赛优秀导师、中医数学实用优秀人才、沈阳优秀科技工作者、沈阳创新创业优秀导师等称号。现担任中国数学学会常务理事、中国药业创新创业基金会秘书长、辽宁省科技创新与人才培养研究主任沈阳军区综合医院伦理委员会常务委员,reviewer of Drug Delivery Journal(SCI)杂志审稿专家等职务。向教授主要从事药物相互作用,药物统计,循证医学,临床试验设计和数据数据挖掘,3D虚拟技术应用,3DP药物设计与数据库研究开发。过去三年向教授主持或参加了全国、省级纵向研究项目10余项及横向项目7余项。截至目前,已发表论文40余篇,其中SCI收录19篇,最高影响因子34;同时作为副主编完成了10多本书籍的编辑工作,以及参加编辑教科书7本。


Rongwu Xiang , associate professor , master tutor ,Vice dean of Medical Equipment Institute for Shenyang Pharmaceutical University.Excellent instructor in Contemporary Undergraduate Mathematical Contest in Modeling 、Liaoning Province hundreds of millions of talent‘hundred levels’candidate 、practical excellent talent of Chinese Medical Mathematical Society、Shenyang outstanding scientific and technological worker、Shenyang innovation and entrepreneurship excellent tutor.Now served as standing director of China Medicine Mathematical Society 、Secretary general of China Pharmaceutical Innovation and Entrepreneurship Fund 、director of Scientific and Technological Innovation and Talent Cultivation Research in Liaoning Province 、 standing Committee of Ethics Committee in Shenyang Army General Hospital 、reviewer of Drug Delivery Journal(SCI)and other duties.Mainly engaged in drug interactions、drug statistics 、evidence-based medicine、 clinical trial design and data statistics 、large data mining、3D virtual technology application 、research and development of 3DP drug design and database .Over the last 3 years , hosted or participated in more than 10 items national 、provincial longitudinal research projects ;presided the horizontal issue of nearly 7 items . Until now , more than 40 papers have been published,of which 19 articles were received as SCI ,the highest IF value was 34 ; deputy editor of more than 10 books ,participated editing 7 textbooks.

徐为人,研究员
天津药物研究院

徐为人,博士,天津药物研究院研究员、药物创新研究中心主任、天津市新药设计与发现重点实验室主任。兼任天津医科大学兼职教授和博士生导师、天津中医药大学兼职教授和硕士生导师、中国药科大学和沈阳药科大学校外硕士研究生导师、中国药理学会生化药理专业委员会委员、国家发改委药品价格评审入库专家、科技部中小企业火炬项目评审入库专家、天津药品审评入库专家、《现代药物与临床》编委、《药品评价研究》编委等。


Weiren Xu, Ph.D. Tianjin Institute of Pharmaceutical Research

EDUCATION

  • Sep.1982 to Jul.1986, B.D. in pharmacy, China Pharmaceutical University, Nanjin, China.
  • Sep.1988 to Jun.1991, M.D. in pharmacology, China Pharmaceutical University, Nanjin, China.
  • Sep. 2000 to Jun. 2004, Ph. D. in physical chemistry , Shandong University, Jinan, China .

EMPLOYMENT

  • 1991-1997  Research Assistant, the department of pharmacology,  Tianjin Institute of Pharmaceutical Research.
  • 1997-2000  Research Associate, the department of pharmacology, Tianjin Institute of Pharmaceutical Research.
  • 2004-      Researcher and Professor , Tianjin Institute of Pharmaceutical Research.
  • 2005-     Director, Dept. of drugs discovery, Tianjin Institute of Pharmaceutical  Research .
  • 2008-2015  Director, Tianjin Key laboratory of molecular design and drug discovery

RESEARCH EXPERIENCE
1991-2000 :

  • Experimental screening and pharmacological evaluation of many drugs including antibiotics, anti allergy drugs, anti inflammation drugs , anti hepatitis drugs .
  • Experimental studies of the pharmacokinetics and bioavailability of many drugs such as aniracetam, nisodipine, carbamazepine, oxcarbazepine, edinafil , simvastadine and so on .

2000-2016 :

  • Studies on the interactions between targets and ligands with docking and MD calculation. The often used software were Schrodinger , Discovery Stadio , Tripos SYBYL, Gaussian, Gromacs , etc.
  • Drug discovery in the fields of diabetes, cardiovascular and inflammatory disease by drug design , synthesis and screening . Now there are two INDs approved for clinical trial in China.

司端运,研究员
天津药物研究院

司端运博士,1984年毕业于山东医学院药学系本科,2001年获得沈阳药科大学药物分析学专业博士学位,2002-2004年期间先后赴法国、美国进行博士后研究,2005年到天津药物研究院工作。
司端运博士现任天津药物研究院研究员,释药技术与药代动力学国家重点实验室常务副主任,中国药学会核心期刊《药物评价研究》杂志副主编,担任中国药理学会药物代谢专业委员会副主任委员、秘书长等。
目前主要从事有机质谱分析研究、新药和新型给药系统的药代动力学评价研究。2005年到天津工作以来先后主持、完成了国家自然基金课题、国家973项目课题、国家科技支撑计划课题等,2009-2010和2012-2015年期间连续主持国家科技重大专项的新药药物代谢动力学研究技术平台建设课题。已经负责完成了60多个IND的DMPK评价研究(已经获得国家I类新药的临床批件有16个),不少已经进入临床阶段,有的已经上市。

近几年来先后被评为天津市优秀留学人员、天津市劳动模范、全国优秀科技工作者和享受国务院政府特殊津贴的专家。
Dr. Duanyun Si received his Ph. D in Drug Metabolism and Pharmacokinetics from Shenyang Pharmaceutical University (Shenyang, China) in 2001 and experienced a staff position as Professor and President, School of Pharmacy, Jining Medical College (Jining, China). He completed two postdoctoral fellowships in Food Nutrient Pharmacokinetics at the INRA Dijon Center (Dijon, France) from 2002-2003, and in Glycomic studies at the Burnham Institute (La Jolla, United States) from 2003-2004, respectively. In 2005, Dr. Si joined Tianjin Institute of Pharmaceutical Research (Tianjin, China) as a PI and professor for new drug/formulation ADME assessment to support the IND/NDA/ANDA drug/formulation development process across China and beyond. In 2009, He became Executive Director in State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, and more recently became the Director in Tianjin Key Laboratory of Pharmacokinetics and Pharmacodynamics. Dr. Si acts as the vice President and Secretary-General in the China’s Society of Studying Xenobiotics, and the Associate Editor of the Journal “Drug Evaluation and Research” which is sponsored by Chinese Pharmaceutical Association. Dr. Si's research interests are focused on drug metabolism, drug disposition, bioanalysis, and organic mass spectrometry to support new drug/formulation ADME/TK/BE assessment during non-clinical and clinical R&D phases.

许明哲,副主任药师
中国食品药品检定研究院

许明哲,副主任药师,中国食品药品检定研究院综合业务处副处长。北京大学药理学学士,协和医科大学药物分析学硕士,现北京大学医药法律与政策博士在读。2008-2009年美国药典委员会访问学者,2013-2014年世界卫生组织总部进修学习。长期从事药品质量研究和业务管理工作,对国外实验室质量管理体系和国际药品监管有较深的了解。参与翻译了《世界卫生组织药品专家委员会技术报告》等论著和其他多类技术文件和指导原则。担任了“首届国际药品快速检测技术论坛”等30余次国际会议大会同声传译。在国内外学术期刊上发表科技论文30余篇,作为编委参编著作3部。


Mr Xu Mingzhe is Deputy Director of General Management Department at NIFDC. He is responsible for the management and coordination of testing business within NIFDC, including pharmaceutical products, biologicals, pharmaceutical packaging materials & excipients, medical devices, food & functional food, cosmetics, etc., and plays a key role in building and sustaining with regulatory agencies, organizations, and quality control institutions/laboratories around the world. Mr Xu has more than seventeen years of experience in the filed of laboratory analytical science and in management. Mr Xu joined NIFDC in 2000 after graduating from Peking Medical University. He worked ten years in quality control and research on antibiotics in laboratory. And then he moved to the management position in charge of the testing business management within NIFDC. He was the visiting scientist working in USP for seven months from September 2008 to April 2009. He also, as a volunteer, worked for WHO in Geneva, Swaziland for six months from October 2013 to April 2014 mainly focusing on the monograph elaboration for the International Pharmacopoeia and WHO Expert Committee on Pharmaceutical Preparation of WHO. He is the first author or corresponding author for more than 40 scientific papers published in pharmaceutical related Journals, and is the co-author of four books. Dr Xu earned his Bachelor of Science degree in Pharmacology from Peking Medical University, his Master Degree of Science in Pharmaceutical Analysis from Peking Union Medical University. And He is working on his Ph.D. (part time) of Medicine Regulation and Policy from Peking University Health Center.

张宏亮,博士
北京夷安君泰管理咨询有限公司

张宏亮,北京夷安君泰管理咨询有限公司董事长,曾任北京大学工学院教授、博士生导师,拥有管理学(北京大学光华管理学院)和管理科学(英国Lancaster大学管理学院)两个博士学位,曾在国际著名项目管理杂志上发表过多篇学术论文,多年来一直担任EURAM、IRNOP会员,及《International Journal of Project Management》、《Project Management Journal》、《管理评论》等专业杂志的审稿专家,《董事会》杂志专栏作家。他是多项创新风险管理方法和工具(包括风险识别、评估和规划地图方法RiskMAP、风险地图软件RiskMap、风险云数据库软件RiskCloud、风险登记簿软件RiskRegister)的发明者,还编制了风险量化分析知识体系以及@Risk软件应用案例库。他曾作为唯一高校专家为国务院国资委风险管理能力提升培训班做主题讲座,得到国务院国资委领导高度赞扬。


Hongliang Zhang is the director of Beijing Yi An Jun Tai Management Consulting Co., Ltd., a former associate professor of Department of Industrial Engineering and Management, Peking University. He got two Ph.D degrees (with management (Peking University Guanghua School of Management) and management science (Lancaster University Management School)). He published a number of academic papers in the prestigious journals such as "International Journal of Project Management", "Project Management Journal", "Management Review" and other professional magazines. He had served as a member of EURAM, IRNOP for many years. He is the inventor of a number of innovative risk management methods and tools (including RiskMAP method (Risk identification, Assessment, Planning and Mapping), RiskMap software, RiskCloud Database, RiskRegister software). He edited the knowledge systems and cases of quantitative risk analysis using @Risk software. He had been the only university expert to do the keynote for the State Council SASAC risk management conference, and was highly praised by the State Council SASAC minister.

耿颖,副研究员
中国食品药品检定研究院

耿颖,中国食品药品检定研究院,化学药品室副研究员,具有多年的近红外光谱分析和化学计量学分析应用经验,负责化学药品对照品标定、进口药品注册检验、质量标准复核及技术复核与验证工作,并开展统计学分析对于药品检验检定和质量控制的应用研究。于2016年1月30日至3月11日赴美国杜克大学医学院(Duke Medical School)生物统计与生物信息学系,执行统计学分析技术在药品质量控制研究中的应用访问任务。 为中国医药信息学会(CMIA)药物分析信息学专业委员会委员。在国际国内杂志共发表专业文章10余篇。


Geng Ying , PhD, who works in National Institutes for Food and Drug Control, Division of Chemical Drug, as an associate research fellow. She had several years of experience on R&D of near-infrared spectroscopic analysis and chemometric analysis, and is responsible for the standardization of chemical reference substances, verification for registration of domestic & imported pharmaceutical products as well as technical adjudication of disputed test. She was tasked with visiting Dept. of Biostatistics and Bioinformatics (Duke Medical School), during 1-30-2016 to 3-11-2016, for the assignment of studying the application of statistical analysis techniques in drug quality control and regulatory research, and began with corresponding research since then. She is a member of medical analysis informatics expert committee of China Medical Informatics Association (CMIA), and the author of more than ten research papers

常艳,副主任药师
中国食品药品检定研究院

常艳,中国食品药品检定研究院抗生素室,副主任药师,CNAS实验室认可技术评审员,三品一械检验检测系统能力验证专家委员会统计组委员。主要研究方向:化学方法对生物学方法的替代(量效统一化)研究;抗生素活性研究;无损技术在药品标准物质研制中的研究与应用;不确定度在药品标准物质和检验领域的应用;统计学在能力验证和标准物质研制工作中的应用;质量管理和实验室认可。目前,作为课题负责人申请的学科带头人培养基金项目处于在研阶段,课题名称:化学药品领域中以质量含量替代生物效价的量效统一化研究。以第一作者身份在国内外杂志发表文章十余篇,其中SCI三篇。


Yan Chang, an associate chief pharmacist, is now the reviewer of China National Accreditation Service for Conformity Assessment (CNAS) for laboratory accreditation and also the member in statistics group of expert committee for proficiency testing of testing system for drug, health food, cosmetics and medical apparatus. Her major research fields are study on alternatives to antibiotic assays (quantitative relationship between the purity and potency), antibiotics activity study, study and application of nondestructive detecting technologies in the preparation of reference standards, application of uncertainty in the field of drug reference standards and testing, application of statistics in the work of proficiency testing and preparation of reference standards, quality control and laboratory accreditation. She is now in charge of the project of academic leader training funds, which is study on the transition from microbiological to physicochemical assays for chemical drugs. She has published more than ten papers in domestic and foreign journals as the first author, three of which are SCI papers.

Jichun Xie, Ph.D.
Duke University Medical Center.

Dr. Jichun Xie got her PhD degree in Biostatistics from University of Pennsylvania in 2011 and had been working at Temple University Fox School of Business for three years. She joined the Department of Biostatistics & Bioinformatics at Duke as an Assistant Professor in July 2014. She is actively involved in the research activities across the Duke Center of Statistical Genetics and Genomics, Duke Cancer Institute, and Duke Department of Neurosurgery. Her research focuses on identifying rare events in complex mixtures, inferring high-dimensional general dependence networks, and their applications in translational biomedical research.


谢季纯博士于2011年获得宾夕法尼亚大学生物统计学博士学位并曾在福克斯大学商学院工作三年。2014年7月,她加入杜克大学生物统计与生物信息学系,任助理教授。她积极地参与杜克统计遗传与基因组学中心、杜克癌症研究所和杜克神经外科系的研究活动。她的研究重点是确定复杂混合物中的罕见事件,推断高维通用依赖网络,及其在转化生物医学研究中的应用。

陈华,研究员
中国食品药品检定研究院

陈华,中检院化药所精麻室副主任,近年来主要研究:1.特殊制剂的质控技术;2.体内滥用药物及兴奋剂检测;3.质控实验室的能力评价等。目前兼任国家麻醉与精神药品的质量标准审评专家; 中国药科大学药物分析专业硕士研究生校外导师;国家总局的实验室能力验证专业委员会委员


Chen Hua ,Deputy Director of NLOND, Division of Chemical Drug Control, NIFDC.
Research Fields:1. Quality Control Technology on special dosage, 2. Detection technology of abused drugs and doping, 3. Quality Evaluation on Medicine Quality Control Laboratory, etc.
Other part-time job: 1. National expert for the specifications of narcotic and psychological medicine products,  2. Master's tutor (part-time) on the medicine analysis, China Pharmaceutical University, 3. The member of Specialized Committee of Proficiency Testing for Laboratory in SFDA.

陈家松
JMP中国区高级顾问

陈家松,JMP中国区高级顾问,ISO9001质量体系主任审核员,精通六西格玛管理理念与实践,熟悉质量管理的各个常用工具,尤其擅长统计分析和实用统计软件的应用,掌握统计分析软件二次开发的能力。在JMP中国区担任咨询顾问期间,为半导体、电子和化工等不同行业的客户提供质量管理和技术培训及其辅导;在希捷工作的十年时间内,作为公司生产工艺,质量改进团队的主导成员,成功完成了多个跨部门合作的六西格玛项目,涵盖产品测试、新产品导入、规模生产、质量改进等各个领域,被公司聘为六西格玛内部讲师。引入先进的统计过程控制方法,并使用JMP编程语言构建实时质量控制系统,提高系统效率,提升产品质量。


Jason Chen,? Senior Consultant of JMP China,Six Sigma Black Belt,ISO9001 Quality System Chief Auditor,Bachelor Degree of Electronic Engineering Soochow University.
Sophisticated in lean & six sigma quality management methodology and practice.
Proficient in statistical analysis tools for product quality improvement or process optimization.
Versed in Statistical analysis software development for process control.
15 years’ experience in high-tech electronics industry for product quality management and process optimization.
As consulting manager of JMP China, responsible for providing quality management consulting services, training, to various kinds of customers in various industries such as semiconductor, electronics and Chemical;
In previously ten years, as the leader of business excellent team in Seagate process engineering division. Help team achieve remarkable success in cross-team projects including new product phase in, product testing, process optimization and etc. Develop new statistical process control methodology and applied in real time product monitoring system with JMP script language, improve system efficiency significantly. As one facilitator of six sigma team provide the training for GB and BB.

周暐
JMP中国区咨询经理

周暐,JMP中国区咨询经理,质量管理分析师,六西格玛黑带大师,中国质量协会六西格玛专家委员会资,上海财经大学统计与管理学院应用统计硕士研究生导师(兼职),精通统计理念与实践,擅长探索性数据分析EDA、实验设计DOE、建模预测、生存Survival分析、统计过程控制SPC、市场调查等统计分析方法在实际工作中的应用 ,曾受邀为礼来,勃林格殷格翰,诺和诺德,华北制药,海正药业,中国石化,宝洁,巴斯夫,中国食品药品检定研究院,上海交通大学医学院,北京大学医学部等国内外著名企业和高等学府培训和辅导统计专业知识,并获得广泛好评。


William Zhou Consulting Manager, JMP China,Quality management analyst, Six sigma Black Belt Master,Professional member of National Six Sigma Implementation Committee, China Association for Quality ,Master's tutor (part-time) of School of Statistics and Management, Shanghai University of Finance and Economics ,Proficient in statistical methodologies and its application, equipped with good knowledge and application experience in Exploratory Data Analysis (EDA), Design of Experiments (DOE), Predictive Modeling, Survival Analysis, Statistical Process Control (SPC), Marketing Research, and so on. Conducted various statistical training and coaching courses to lots of technicians from different companies or organizations, such as Lilly, Boehringer-Ingelheim, Novonordisk, North China Pharm, Hisun Pharm, Sinopec, P&G, BASF, National Institutes for Food and Drug Control, Medical School of Shanghai Jiaotong University, Medical School of Peking University, and received positive feedback.

谭德讲,主任技师
中国食品药品检定研究院

谭德讲,中国食品药品检定研究院药理室副主任,主任技师。曾先后在日本大正制药株式会社和意大利高级卫生研究院进行药理研究;主要从事药品的生物检定、药效与毒性研究与评价和统计学在药品质量监管中的应用研究。在国内外学术期刊发表学术论文70余篇,其中SCI收录7篇;参与编写学术著作7部。主要专业兼职有:中国海洋大学生命学院客座教授、中国药科大学和烟台大学兼职校外硕士生导师;国家食品药品监督管理总局(CFDA)医疗器械审评专家,CFDA实验室能力验证专业委员会委员;国家自然科学基金、国家科技奖励和北京市科技奖励等的评审专家;农工党北京市主委会医药卫生工作委员会委员。药物分析杂志编委;山东大学学报(医学版)通讯编委。


Tan De-jiang, is currently a senior researcher and deputy director at Dept. of Pharmacology Lab., Institute of Chemical Drug Control (ICDC), National Institutes for Food and Drug Control (NIFDC). once worked at Instituto Superiore di Sanita in Italy (2000-2002) and Taisho Pharmaceutical Co., LTD in Japan (1998-1999) for the pharmacological research besides NIFDC. His professional research interests are focused on the efficacy, toxicity research of medicine & medical device and applied statistical application research. He is the author or co-author of over 70 papers and 7 books. Prof. Tan’s other main profession positions are: Adjunct Professor of Ocean University of China; Master's tutor on the medicine analysis in China Pharmaceutical University and YanYai University; Expert member for Medical Device evaluation at Chinese Food and Drug Administration (CFDA); Expert member for science foundation evaluation at National Natural Science Foundation of China, and the expert member for science & technology awards evaluation at National & Beijing Office for Science & Technology etc.. He is the member of the Editorial Board of the Chinese Journal of Pharmaceutical Analysis.
距离会议开幕还有
会议日期

2017年5月18-19日

网上注册截止日期

2017年5月17日

现场报到日期

2017年5月17日